ANTILIPEMIC AGENT;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
STATIN;
ATHEROSCLEROSIS;
CARDIOVASCULAR RISK;
CHOLESTEROL BLOOD LEVEL;
CHRONIC KIDNEY DISEASE;
CLINICAL PRACTICE;
DRUG INDICATION;
DYSLIPIDEMIA;
EDITORIAL;
HUMAN;
INSULIN DEPENDENT DIABETES MELLITUS;
LIFESTYLE;
MEDICAL DECISION MAKING;
NON INSULIN DEPENDENT DIABETES MELLITUS;
PRACTICE GUIDELINE;
PREVENTIVE MEDICINE;
RISK REDUCTION;
SOUTH AFRICA;
TREATMENT OUTCOME;
TREATMENT PLANNING;
VASCULAR DISEASE;
WEIGHT REDUCTION;
ANTICHOLESTEREMIC AGENTS;
CAUSE OF DEATH;
CEREBROVASCULAR ACCIDENT;
CHOLESTEROL, LDL;
CROSS-CULTURAL COMPARISON;
HUMANS;
HYPERCHOLESTEROLEMIA;
MYOCARDIAL INFARCTION;
PRACTICE GUIDELINES;
SOUTH AFRICA;
Diagnosis, management and prevention of the common dyslipidaemias in South Africa - Clinical Guideline, 2000
South African Medical Association and Lipid and Atherosclerosis Society of Southern Africa Working Group. Diagnosis, management and prevention of the common dyslipidaemias in South Africa - Clinical Guideline, 2000. S Afr Med J 2000; 90: 164-178.
Expert Panel on detection, evaluation, and treatment of high cholesterol in adults. Executive summary of the third report of the National Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Expert Panel on detection, evaluation, and treatment of high cholesterol in adults. Executive summary of the third report of the National Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
European guidelines on cardiovascular disease prevention in clinical practice
De Backer G, Ambrosioni E, Borch-Johnson K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-1610.
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial
MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention
Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003; 108: 2154-2169.
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka H-M, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.